Spinal cord injury

Keywords:

Products News

Chronic heart failure


Chronic heart failure lies in the end stage of development of many cardiovascular diseases. Problems such as coronary heart disease, hypertensive heart disease and cardiomyopathy may all eventually develop into chronic heart failure, when cardiac function is seriously impaired with structural changes. As the heart is unable to pump enough blood supply to organs and meet metabolic needs at this time, a number of precarious complications may follow with a high mortality rate.

(Case I)Severe traumatic brain injuries caused by traffic accident


A 7 year old boy was hit by car. The accident caused widespread injury to his brain, leaving him in a vegetative state. He became quadriplegia with no bowel or bladder control. Rehabilitation treatments didn’t work on him.

(Case II) Alzheimer's disease


75 year old female with Alzheimer's disease: aggressive, family members not recognized, no memory recall, full time caretaker, no response to other treatments.

(Case IV) Stroke sequelae


60 year old male with a height of 190cm: suffering from brain stem stroke, less than 97 pounds, food pureed & G tube delivered, without speech, “locked in” syndrome, completely paralyzed, less than seven months to live. Other treatment options did not work.

New Progress Achieved in Jiuzhitang M&A Fund’s Investment in Stem Cell Business


On January 12, 2019, Jiuzhitang Co., Ltd. made an announcement on latest progress its M&A fund achieved in investment efforts. ...

New Progress Achieved in Jiuzhitang M&A Fund’s Investment in Stem Cell Business


On January 12, 2019, Jiuzhitang Co., Ltd. made an announcement on latest progress its M&A fund achieved in investment efforts. ...

Jiuzhitang Maker selected as one of the Ten Key companies received “Comprehensive Service Package” offered by Daxing District


Daxing District Development and Reform Commission and Daxing Biomedicine Industry Base delivered “Comprehensive Service Package”...

Stem cell drugs formulated with Stemedica’s products approved in Kazakhstan for treatment of acute myocardial infarction


On 12 September 2018, Stemedica completed its Phase III clinical trial of using mesenchymal stem cells to treat acute myocardial infarction ...